PT  - JOURNAL ARTICLE
ED  - , 
TI  - SHP2 Inhibition May Resensitize NSCLC Tumors to ALK Inhibitors
AID  - 10.1158/2159-8290.CD-RW2018-043
DP  - 2018 May 01
TA  - Cancer Discovery
PG  - OF10--OF10
VI  - 8
IP  - 5
4099  - http://cancerdiscovery.aacrjournals.org/content/8/5/OF10.short
4100  - http://cancerdiscovery.aacrjournals.org/content/8/5/OF10.full
SO  - Cancer Discov2018 May 01; 8
AB  - Targeting SHP2 suppresses ALK inhibitor resistance caused by tyrosine kinase reactivation.